Key presentations on chronic spontaneous urticaria (CSU) at the American Academy of Dermatology 2025 include late-breaking data on the anti-c-Kit antibody briquilimab and positive results for remibrutinib, as reported by Dr Jennifer Hsiao from the University of Southern California, Los Angeles.
Dr Hsiao begins by highlighting ongoing efforts at the conference to develop new consensus guidelines for CSU. For cases resistant to antihistamines, the draft guidelines propose adding dupilumab, an IL-4 and IL-13 inhibitor, and remibrutinib, a BTK inhibitor, when these two medications are on label, alongside omalizumab as preferred options for treatment following antihistamine failure.
She then reviews a late-breaking presentation on findings from a phase 1b/2a study of the anti-c-Kit antibody briquilimab. The study reported significant improvement in the urticaria activity score (UAS7) at 12 weeks among patients who remained symptomatic despite treatment with antihistamines and omalizumab, with no severe safety concerns observed.
Finally, she discusses data on sleep and activity interference in patients with CSU, from the phase 3 REMIX-1 and REMIX-2 trials evaluating the oral BTK inhibitor remibrutinib. The results showed improvements in sleep (SIS7) and activity (AIS7) scores as early as the first week of treatment. Over 60% of remibrutinib-treated patients achieved a SIS7 score of 0 at week 52, with similar trends in AIS7 scores — an important finding given the significant sleep disturbances experienced by CSU patients.
